| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 58.58 | 19.1% | 35.1% |
| Total Income | 58.58 | 19.1% | 35.1% |
| Expenditure | 32.16 | 6.4% | 17.1% |
| PBT | 26.38 | 34.9% | 42.5% |
| Net Profit | 15.69 | 46.8% | 22.4% |
| OPM | 45.09% | 6.55pp | 8.46pp |
| NPM | 26.79% | 5.05pp | 2.79pp |
| EPS | 0.15 | 50.0% | 25.0% |
SBC Medical Group Holdings Reports 3Q 2026 Financial Results
13 Nov 2026 · 13 Nov, 5:26 pm
Summary
SBC Medical Group Holdings reported a strong third quarter of fiscal year 2026 with total revenues of $59 million, a 35% increase year-over-year. Income from operations surged by 66% to $26 million, and net income attributable to SBC Medical grew 22% to $16 million. The company also saw significant improvements in profitability, with Adjusted EBITDA up 66% to $28 million and the Adjusted EBITDA margin expanding to 47%. Management highlighted the reacceleration in growth driven by structural reforms and the strength of their MSO model, with plans to invest further in AI and technology to enhance profitability and efficiency.
Key Highlights
- 1
Total revenues were $59 million, an increase of 35% year-over-year for the third quarter of fiscal year 2026.
- 2
Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%.
- 3
Net income attributable to SBC Medical was $16 million, up 22% year-over-year, reaching a net income margin of 27%.
- 4
Adjusted EBITDA was $28 million, up 66% year-over-year, with the Adjusted EBITDA margin expanding 9 percentage points to 47%.
- 5
Basic earnings per share (EPS) was $0.15, an increase of 25% year-over-year.
- 6
The clinic network increased by 36 locations year-over-year to 293 locations as of September 30, 2026.
- 7
Patient visits over the trailing twelve months totaled 7.06 million, up 9% year-over-year.
Management Comments
Yoshiyuki Aikawa
The third quarter of 2026 marked a strong reacceleration in SBC Medical’s growth. Revenue increased 35% year-over-year, income from operations rose 66%, and net income attributable to SBC Medical rose 22%, with a net income margin of 27% and an Adjusted EBITDA1 margin of 47%. Following the structural reforms implemented in 2025, growth and profitability are improving in tandem, demonstrating the strength of our highly profitable MSO model. Our MSO revenue growth is supported by two key levers: expanding our clinic network and increasing service fees per clinic. Our goal is not simply to add locations. We aim to raise productivity and profitability at the clinics we support while expanding the network efficiently. This quarter’s growth in management services revenue, including the effect of service fee revisions, demonstrates progress in this model. To strengthen this model further, we are investing in AI and technology. Specifically, we are developing a proprietary local large language model (LLM) infrastructure designed to enable the secure use of medical data while optimizing AI costs, while also advancing our clinic operating systems through our capital and business alliance with Atomic Software. Together, these initiatives are intended to improve profitability at existing clinics and make new clinic openings more efficient, enabling our scalable MSO platform to generate greater earnings power as the business expands. Our Longevity business, which we view as our next growth opportunity, is also making tangible progress. As a first step, we are developing an in-house DNA methylation-based test to estimate biological age, drawing on the Waqoo Group’s research and technology capabilities. By adding diagnostics to our existing medical network and combining AI with physicians’ expertise, we aim to build an integrated platform spanning testing, personalized treatment and evaluation of outcomes. In Japan, we will continue expanding our multi-brand presence in aesthetic dermatology and broadening our non-aesthetic medical services. Internationally, we are pursuing collaboration with OrangeTwist in the United States and expansion across ASEAN markets. These initiatives are designed to unlock further growth in our existing business while pursuing opportunities in new markets. For the first nine months of 2026, net cash provided by operating activities totaled $50 million. As of September 30, 2026, we held $198 million in cash and cash equivalents and $154 million in Net Cash4. We intend to deploy this strong financial position toward disciplined growth investment, with the goal of sustaining EPS growth over the medium- to long-term and enhancing corporate value.
Informational and educational content only. Not investment advice.